In 2021, the sales volume of Innovent's PD-1 exceeded RMB 3 billion

Some time ago, industry insiders were shocked by the news that the sales volume of Key-tru-da in a year was more than RMB 112.5 billion and they even be green with envy. However, Chinese PD-1 also sells well. According to the quarterly sales data of Innovent's sintilimab (trade name: Tyvyt), its sales volume was about RMB 3.1 billion in 2021 (nominal sales revenue).

At present, four indications of sintilimab have been approved for marketing, and three indications are under review for listing application. 

It is worth mentioning that in December 2021, sintilimab became the only PD-1 inhibitor with four approved indications, including first-line non-squamous non-small cell lung cancer (NSCLC), first-line squamous non-small cell lung cancer (NSCLC), first-line liver cancer and Hodgkin's lymphoma, all of which were included in national health insurance. 

In addition, in May 2021, the listing application of sintilimab combined with pe-me-trexed and platinum drugs for first-line treatment of non-squamous NSCLC has been formally accepted and reviewed by FDA. 

With all four approved indications being included in health insurance, and three indications to be approved, the sales volume of sintilimab is predicted to increase year by year in the next 2-3 years. 

About  the Author:    

Caicai, a Master of Pharmacy from Shanghai Jiaotong University, used to work in the Institute of Science and Technical Information. Currently as a practitioner in the drug surveillance system, she is good at interpreting industry regulations, pharmaceutical research developments, etc.